This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The 1nhaler drug delivery device enables many different dry powder drugs to be readily delivered in a sustainable, low-cost format. The DPI is cardboard-based, with the same dimensions as a credit card, and the discreet platform technology includes a breathable membrane that can be tailored to deliver individual drugs to patients.
1nhale’s recently acquired $2.5 million investment will allow the company to work with other companies around the world to bring new and existing drugs to patients in a more efficient and affordable way through the creation of the next generation of inhaled products.
The funding round was led by Archangels with support from Dr. Yusuf Hamied, British Business Investments (BBI), and seed investors. Dr. Hamied, non-executive chairman of Indian pharmaceutical giant Cipla, is globally respected in the field for pioneering the manufacture of affordable drugs for developing countries to fight AIDS and other life-threatening diseases.
Based in Edinburgh, 1nhaler has a team of industry experts, with decades of experience taking inhaled products to market, including Chief Scientific Officer Helen Muirhead who had responsibility for GSK’s respiratory portfolio, including the Diskus and Ellipta inhalers.
“Our DPI has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, revolutionizing the delivery of critical drugs, without the cost and environmental impact of existing devices,” says Lisa McMyn, 1nhalers founder and chief executive officer. “Securing funding from Archangels is invaluable for the next steps in the 1nhaler’s development. Their life sciences expertise and patient capital approach are exactly what we’re looking for in a funding partner.”
